Joshua M. Eizen, Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics, Inc., filed a Form 4 on November 6, 2026, disclosing a sale of common stock on November 5, 2026, to cover tax withholding obligations from vesting RSUs.
Key Highlights
- Shares sold: Eizen disposed of 2,826 shares of AN2 Therapeutics common stock on November 5, 2026, at a price of $4.22 per share.
- Purpose of sale: According to the filing, the shares were sold pursuant to grant terms to satisfy tax withholding obligations arising from RSU vesting on November 4, 2026.
- Post-transaction ownership: Eizen beneficially owned 207,546 shares following the reported transaction, held directly.
- RSU holdings: The filing discloses four tranches of outstanding RSUs totaling 170,000 RSUs, each vesting at 1/4th annually over four years from various start dates between January 1, 2024 and January 1, 2026.
- ESPP purchase included: The post-transaction total reflects the purchase of 3,818 shares under the issuer's 2022 Employee Stock Purchase Plan on September 30, 2026.
- Signing authority: The form was signed by Lucy Day as Attorney-in-Fact for Joshua M. Eizen on November 6, 2026.
AN2 Therapeutics COO and CLO Eizen Reports RSU-Related Share Disposal
According to the Form 4 filed with the SEC on November 6, 2026, Joshua M. Eizen, identified in the filing as Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics, Inc. (NASDAQ:ANTX), sold 2,826 shares of common stock on November 5, 2026, at $4.22 per share. The filing states that this sale was made pursuant to grant terms "to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units" that vested on November 4, 2026, and was coded as a disposition (transaction code "S") in Table I of the form.
Following the reported transaction, Eizen's direct beneficial ownership stood at 207,546 shares. The filing notes that this figure reflects an adjusted total that includes the purchase of 3,818 shares under the issuer's 2022 Employee Stock Purchase Plan on September 30, 2026. No derivative securities transactions were reported in Table II of the form.
The filing also details Eizen's outstanding RSU positions across four grants: 30,000 RSUs vesting from January 1, 2024; 31,500 RSUs vesting from November 4, 2024; 58,500 RSUs vesting from January 1, 2025; and 50,000 RSUs vesting from January 1, 2026. Each tranche vests at 1/4th annually over four years, in each case subject to the reporting person's continuous service as of each vesting date, according to the filing.
What Was Disclosed
Eizen's Form 4 discloses a sale of 2,826 common shares at $4.22 on November 5, 2026, made to cover RSU-related tax withholding, leaving him with direct beneficial ownership of 207,546 shares in AN2 Therapeutics.




Please wait processing your request...